



Media Contacts

Carol Berry, MBA
Chief Business Officer, SVP
Caprion
cberry@caprion.com
514.360.3600

Caprion/ImmuneCarta Highlights Data Presented by Adaptimmune at the 2015 American Society of Gene and Cell Therapy Annual Meeting

Enhanced-affinity NY-ESO-1-specific T cells exhibit extended functionality without exhaustion in a pattern of effector and memory programming in multiple cancer indications

Montreal, Canada – May 13, 2015— Caprion announced today that Adaptimmune will present data at the American Society of Gene and Cell Therapy Annual Meeting on Friday May 15th in the Immunotherapy Session from 3:30pm- 5:30pm.

Adaptimmune is conducting Phase 1/2 clinical trials for its NY-ESO TCR therapeutic in cancer patients including patients with synovial sarcoma and multiple myeloma. Affinity enhanced T cells specific for the NY-ESO-1 cancer testis antigen were administered to patients with synovial sarcoma and multiple myeloma. The data being presented relates to the phenotypic and functional evaluation of the engineered T cells administered to patients and the data may suggest that the engineered autologous T cells administered can expand and persist in patients without exhibiting signs of T cell exhaustion. Yoav Peretz, Ph.D., Scientific Director at Caprion's ImmuneCarta Division said, "We are privileged to work with Adaptimmune in these pioneering studies in the field of Immuno Oncology and excited by the potential for our ImmuneCarta assays to help further the understanding of immune correlates of protection."

Martin LeBlanc, CEO of Caprion, stated, "These results provide another tangible illustration of Caprion's ability to collaborate with leading biotech and pharma companies and to deliver valuable immunological insights in support of their clinical development objectives."

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta™, offers proprietary multi-parametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion's proteomics business unit, ProteoCarta®, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins

across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.